We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
19th Mar 20204:43 pmRNSSecond Price Monitoring Extn
19th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSCorporate Update
12th Mar 20204:42 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 202012:02 pmRNSPrice Monitoring Extension
7th Feb 20204:35 pmRNSPrice Monitoring Extension
28th Jan 20204:40 pmRNSSecond Price Monitoring Extn
28th Jan 20204:35 pmRNSPrice Monitoring Extension
28th Jan 20207:00 amRNSCorporate Update
22nd Jan 20204:40 pmRNSSecond Price Monitoring Extn
22nd Jan 20204:35 pmRNSPrice Monitoring Extension
17th Jan 202012:12 pmRNSHolding(s) in Company
16th Jan 20204:41 pmRNSSecond Price Monitoring Extn
16th Jan 20204:35 pmRNSPrice Monitoring Extension
16th Jan 202012:07 pmRNSSecond Price Monitoring Extn
16th Jan 202012:02 pmRNSPrice Monitoring Extension
14th Jan 202012:35 pmRNSHolding(s) in Company
10th Jan 20209:55 amRNSHolding(s) in Company
6th Jan 20204:40 pmRNSSecond Price Monitoring Extn
6th Jan 20204:35 pmRNSPrice Monitoring Extension
3rd Jan 202010:42 amRNSHolding(s) in Company
23rd Dec 20199:45 amRNSHolding(s) in Company
19th Dec 20194:29 pmRNSHolding(s) in Company
19th Dec 20194:25 pmRNSHolding(s) in Company
10th Dec 20197:00 amRNSVoluntary delisting from the NASDAQ Capital Market
6th Dec 201911:14 amRNSHolding(s) in Company
29th Nov 201912:20 pmRNSHolding(s) in Company
29th Nov 20197:00 amRNSTotal Voting Rights
27th Nov 20197:00 amRNSADS Program and Warrant Agent Agreement
26th Nov 20197:00 amRNSVoluntary Delisting from the Nasdaq Capital Market
20th Nov 20195:51 pmRNSHolding(s) in Company
18th Nov 201912:12 pmRNSDirectorate Changes
14th Nov 20196:13 pmRNSResult of General Meeting
11th Nov 20197:00 amRNSSettlement Agreement
28th Oct 20194:14 pmRNSHolding(s) in Company
25th Oct 20193:51 pmRNSHolding(s) in Company
25th Oct 201912:07 pmRNSSecond Price Monitoring Extn
25th Oct 201912:02 pmRNSPrice Monitoring Extension
25th Oct 20197:00 amRNSPosting of Circular and Notice of General Meeting
24th Oct 20197:00 amRNSU.S. Army-funded project to Evaluate Iclaprim
21st Oct 20193:00 pmRNSTiming of General Meeting and Circular
21st Oct 201912:07 pmRNSSecond Price Monitoring Extn
21st Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20197:00 amRNSMotif Bio confirms receipt of FDA meeting minutes
3rd Oct 201912:07 pmRNSSecond Price Monitoring Extn
3rd Oct 201912:02 pmRNSPrice Monitoring Extension
3rd Oct 20197:00 amRNSChange of Adviser
2nd Oct 20197:00 amRNSConditional Placing
30th Sep 20194:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.